Navigation Links
A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
Date:5/1/2013

BURLINGTON, Mass., May 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a greater effect on depressive symptoms than current treatments is one of the greatest unmet needs in patients with treatment-resistant depression (TRD)*, according to insights from surveyed psychiatrists in the United States and Europe as well as U.S. managed care organizations' (MCOs') pharmacy directors. Pharmacological treatment for TRD most typically involves switching, combining (two antidepressants from different classes) or augmenting (combining another agent with an antidepressant). The atypical antipsychotics Abilify (Bristol-Myers Squibb/Otsuka Pharmaceutical's aripiprazole) and Seroquel XR (AstraZeneca's quetiapine XR, generics in the United Kingdom and Germany) are two therapies approved as adjunct therapies to antidepressants in the U.S. and are also used in this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO

"Adjunctive treatment with atypical antipsychotics, though considered effective by thought-leaders, generally results in significant weight gain, and so emerging therapies could differentiate themselves in the marketplace by demonstrating both efficacy in TRD and by having a more tolerable weight gain profile," said Decision Resources Analyst Alana Simorellis , Ph.D.

The DecisionBase 2013 report entitled In the Crowded Antidepressant Market Space, What Are the Remaining Opportunities for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. This finding suggests that cost-sensitive payers consider efficacy improvements to be of greater value than improvements in tolerability.

Surveyed U.S. psychiatrists expect to prescribe Eli Lilly's emerging therapy edivoxetine to 25 percent of their patients with TRD. Decision Resources forecasts that edivoxetine will earn a U.S. patient share for TRD similar to surveyed psychiatrists' estimate by 2021, based on top-line results from Phase II/III trials of edivoxetine as an adjunct therapy to SSRIs and positive Phase II/III monotherapy results in patients with major depressive disorder.

Clinical data and the opinions of interviewed thought leaders indicate that, among emerging therapies profiled in the report, Eli Lilly's edivoxetine shows considerable promise as an adjunct to antidepressant therapy. Additionally, edivoxetine appears to offer a more favorable profile in terms of neurological side effects and risk of weight-gain relative to the atypical antipsychotics.

*The majority of physicians interviewed and surveyed by Decision Resources consider a patient "treatment-resistant" if depressive symptoms persist despite treatment with at least two different trials of antidepressant drugs from two different drug classes.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 

 

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
2. Cancer drug shortages mean higher costs and greater risk for patients
3. New Report Details NCPA Efforts to Drive Greater Medication Adherence
4. Greater New York Dental Meeting and Inside Dental Technology Announce Collaboration 2013
5. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
6. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
7. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
8. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
9. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
Breaking Medicine News(10 mins):